

# LONG-LASTING RESPONSE TO CYCLOPHOSPHAMIDE IN A PATIENT WITH ANTI-CONTACTIN-1 ANTIBODY POSITIVE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY AND MEMBRANOUS GLOMERULONEPHRITIS.

G.Piccolo, A. Cortese, E. Zardini, S. Romagnolo, E. Alfonsi, J. Devaux \*, D. Franciotta

C.Mondino National Neurological Institute, Pavia, Italy, \*CNRS, CRN2M-UMR7286, Aix-Marseille University, Marseille, France

## Background

Anti-contactin-1 (CNTN1) antibodies of the IgG4 isotype have been recently detected in a subgroup of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) showing acute/subacute onset of severe sensorimotor polyneuropathy, early axonal damage and poor response to intravenous immunoglobulin (IVIg) and corticosteroids. The anti-CNTN1 antibody pathogenic mechanism seems to be related to the physical interaction with CNTN1-neurofascin 155 (NF155) complex at paranodes, leading to loss of nodal integrity. Treatment of these patients is challenging. We report a patient with anti-CNTN1 antibody-positive CIDP and membranous glomerulonephritis (MGN) showing a long-lasting response to cyclophosphamide.

## Case Report

Male, 70 yo, Caucasian, no relevant past medical history

### 2004

#### Neurological symptoms and signs:

Pins-and-needles sensation at lower limbs progressing to upper limbs, walking difficulties progressing within a month

Proximal and distal muscle weakness (3-4 MRC)  
Absent DTR, "stoking&glove" pattern of hypoesthesia, LL impaired vibratory sense and SK; sensory ataxia; gait with double support

#### CSF:

CSF protein: 142 mg/dL, cell count: 1

#### EMG:

Demyelinating polyneuropathy

#### Sural nerve biopsy:

Diffuse loss of myelinated fibers

Diagnosis ACUTE POLYRADICULONEURITIS

Treatment Ivlg

Outcome No clinical and functional improvement

#### Subsequent clinical course:

worsening of lower limb weakness + ankles swelling

#### Blood test:

anemia, low serum albumin, proteinuria (up to 10 g/24h)

#### Kidney biopsy:

consistent with MGN

Diagnosis NEPHROTIC SYNDROME

Treatment Prednisone 50 mg/die

Outcome Improvement of kidney function, neurological function substantially unchanged

### 2005

#### Neurological symptoms and signs:

substantially unchanged

#### MRI:

mild enlargement of spinal nerve roots (Gd not administered due to kidney failure)

#### Blood analysis:

CBC, ESR, ANA, ANCA, FR, serum and urine immunoelectrophoresis, anti-ganglioside antibodies: negative

#### CSF:

albumin: 83 mg/dL, CSF cell count: <2

#### Kidney biopsy:

confirms pathologic features of MGN stage I, with subepithelial deposits of immune complexes and complement deposition (C3). No evidence of vasculitis or amyloid deposits

Diagnosis CIDP + ANCA-NEGATIVE MGN

Treatment 1g iv cyclophosphamide monthly for 6 months; slow prednisone tapering

Outcome Normalization of muscle strength and partial improvement of sensory ataxia; unassisted gait; normalized renal function



### 2016

#### Subsequent neurological course:

stable neurological and kidney function; no further immunosuppressive treatment required

#### Neurological examination:

normal muscle strength, weak DTR, hand finger and distal LL hypoesthesia, LL impaired toes vibratory sense and SK, slight sensory ataxia (unassisted gait)



## Conclusions

The clinical features of our patient fit with the mostly reported ones in patients with anti-CNTN1 antibody positive CIDP. As recently reviewed, CIDP has rarely been reported in association with MGN. CNTN1 protein is expressed at low levels in kidney and might represent a shared antigen target with peripheral nervous tissue. However, in the only other patient reported with anti-CNTN1 antibody positive CIDP and MGN, binding assays on mouse kidney sections did not show increased reactivity with respect to normal controls. Despite all limitations of a single case observation, our report suggests that cyclophosphamide could be considered an effective therapy in anti-CNTN1 antibody-associated CIDP and MGN.

## References

1. Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015; 138: 1484-1499.
- 2.2. Doppler K, Appeltshausen L, Wilhelmi K, et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 2015; 86: 720-728.
3. Yi Wong AH, Kokubun N, Fukami Y, et al. Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy. J Peripher Nerv Syst 2015; 20: 63-66.